TrialClinical and translational medicine2025

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis.

Shang-Gin Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.